Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.55 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.50 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL927807 | 1.00 | KMT2A (0.57) | KMT2AP2RX7FKBP1AGAAALDH1A1 | |
| SCHEMBL24434796 | 1.00 | KMT2A (0.57) | KMT2AP2RX7FKBP1AGAAALDH1A1 | |
| SCHEMBL5741011 | 0.96 | KMT2A (0.54) | KMT2AP2RX7FKBP1AGAAALDH1A1 | |
| SCHEMBL22452838 | 0.92 | CAPN1 (0.58) | KMT2AP2RX7FKBP1AALDH1A1HCRTR1 | |
| SCHEMBL28681218 | 0.92 | CAPN1 (0.58) | KMT2AP2RX7FKBP1AALDH1A1HCRTR1 | |
| SCHEMBL19975250 | 0.88 | ALDH1A1 (0.66) | KMT2AFKBP1AALDH1A1CYP2C19TSHR | |
| SCHEMBL17319526 | 0.87 | KMT2A (0.74) | KMT2AGAAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL12471703 | 0.87 | KMT2A (0.74) | KMT2AGAAALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL10377790 | 0.87 | P2RX7 (0.60) | KMT2AP2RX7GAAALDH1A1CYP2C9 | |
| SCHEMBL7491535 | 0.86 | KMT2A (0.58) | KMT2AGAAHDAC1HDAC6HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3919056-B1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2022-12-20 | — | — | US | disclosed |
| EP-2049478-B1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LTD (GB) | 2012-05-30 | — | — | EP | disclosed |
| CN-101511787-B | Substituted N-phenylmethyl-5-oxo-proline-2-amides as P2X 7-receptor antagonists and methods of their use | GLAXO GROUP LTD. (GB) | 2011-11-30 | — | — | CN | disclosed |
| US-8048907-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2011-11-01 | — | — | US | disclosed |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED | 2010-06-10 | — | — | US | disclosed |
| US-7718693-B2 | Receptor antagonists and their methods of use | GLAXO GROUP LIMITED (GB) | 2010-05-18 | — | — | US | disclosed |
| CN-101511787-A | Substituted N-phenylmethyl-5-oxo-proline-2-amides as P2X 7-receptor antagonists and methods of their use | GLAXO GROUP LTD (GB) | 2009-08-19 | — | — | CN | disclosed |
| WO-2009074518-A1 | COMBINATIONS OF PROLINAMIDE P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| EP-2049478-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | Glaxo Group Limited (GB) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008003697-A1 | SUBSTITUTED N-PHENYLMETHYL -5-OXO-PROLINE-2-AMIDES AS P2X7-RECEPTOR ANTAGONISTS AND THEIR METHODS OF USE | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | WO | disclosed |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | GLAXO GROUP LIMITED (GB) | 2008-01-10 | — | — | US | disclosed |
| US-6818643-B1 | 3,9-DIAZABICYCLO(3.3.1)NONAN-2-ONE DERIVATIVES; PEPTIDYL-PROLYL ISOMERASE (PPIASE OR ROTAMASE) INHIBITORS; NEUROPROTECTIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-16 | — | — | US | disclosed |
| WO-2001042245-A1 | NEUROTROPHIC BICYCLIC DIAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-06-14 | — | — | WO | disclosed |
| EP-0381959-B1 | Cyclohexaneacetamide derivatives | HOFFMANN LA ROCHE (CH) | 1995-05-03 | — | — | EP | disclosed |
| US-5015653-A | Posess Cognitive Enhancement And Antiamnestic Activity | HOFFMANN-LA ROCHE INC. (US) | 1991-05-14 | — | — | US | disclosed |
| EP-0381959-A1 | Cyclohexaneacetamide derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1990-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322704-A1 | COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN | HBG2, HBG1, HBB | KMT2A 2167/4885P2RX7 4597/4885FKBP1A 1139/4885 |
| US-20080009541-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | KMT2A 4700/4885P2RX7 1/4885FKBP1A 481/4885 |
| US-20100144829-A1 | Novel Receptor Antagonists and Their Methods of Use | P2RX7, P2RX3, P2RX1 | KMT2A 4700/4885P2RX7 1/4885FKBP1A 481/4885 |
| US-11530191-B2 | Compounds and uses thereof for the modulation of hemoglobin | HBG2, HBG1, HBB | KMT2A 2167/4885P2RX7 4597/4885FKBP1A 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.